Acute pancreatitis : Patients should be monitored for persistent severe abdominal pain Acute gallbladder disease : Including cholelithiasis and cholecystitis
Improved health markers: In addition to weight loss, patients can anticipate improved health markers and lab results, such as balanced blood sugar, cholesterol, and blood pressure levels
Weekly body weight measurements confirmed that the low dose of semaglutide (30 nmol/kg biweekly) did not alter body weight over the 16-week treatment period Figure 1B and semaglutide treated rats continued to gain weight during the 16 week experimental protocol
As GLP-1 medications make their way out of exam rooms and into group chats, Instagram comments and happy hour conversations, microdosing keeps coming up
The clinical presentation of the cases reported to date suggest additional contaminants may be contributing to the observed liver toxicity in the products
Sugar alcohols (sorbitol, xylitol) and artificial sweeteners may exacerbate GI distress in sensitive patients
